T1	Participants 23 73	patients treated for Helicobacter pylori infection
T2	Participants 87 116	Helicobacter pylori infection
T3	Participants 357 452	795 adults with preneoplastic gastric lesions was randomised to receive anti-H pylori treatment
T4	Participants 1596 1604	patients
T5	Participants 1668 1711	patients with preneoplastic gastric lesions
